Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )
NCT ID: NCT01350791
Last Updated: 2017-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3001 participants
OBSERVATIONAL
2010-05-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Effectiveness and Safety of the GENOUS STENT (IRIS-GENOUS STEMI)
NCT01348373
Evaluation of Effectiveness and Safety of BIOMATRIX Stent (IRIS-BIOMATRIX)
NCT01350778
Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)
NCT01348399
The IRIS-Resolute Integrity (IRIS-Integrity)
NCT01392846
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
NCT01186120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, there have been limited data regarding comparison of PROMUS Element stent with first-generation DES in routine clinical practice. Therefore, we perform large-scale real-world registry of PROMUS Element stents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Promus Element stent
Patients receiving Promus Element stents
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion Criteria
* Terminal illness with life expectancy \<1 year
* Patients with cardiogenic shock
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CardioVascular Research Foundation, Korea
OTHER
Boston Scientific Corporation
INDUSTRY
Seung-Jung Park
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seung-Jung Park
MD,PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seung-Jung Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Ki Bae Seung, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul St. Mary's Hospital, Catholic University of Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
38 Centers
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVRF2010-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.